WO1998032849A3 - Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications - Google Patents

Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications Download PDF

Info

Publication number
WO1998032849A3
WO1998032849A3 PCT/EP1998/000433 EP9800433W WO9832849A3 WO 1998032849 A3 WO1998032849 A3 WO 1998032849A3 EP 9800433 W EP9800433 W EP 9800433W WO 9832849 A3 WO9832849 A3 WO 9832849A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
diagnostic
therapeutic applications
corresponding polypeptide
polynucleotide associated
Prior art date
Application number
PCT/EP1998/000433
Other languages
French (fr)
Other versions
WO1998032849A2 (en
Inventor
Christine Petit
Sonia Abdelhak
Kalatzis Vasiliki
Sylvie Compain
Christophe Vincent
Dominique Weil
Original Assignee
Pasteur Institut
Christine Petit
Sonia Abdelhak
Kalatzis Vasiliki
Sylvie Compain
Christophe Vincent
Dominique Weil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Christine Petit, Sonia Abdelhak, Kalatzis Vasiliki, Sylvie Compain, Christophe Vincent, Dominique Weil filed Critical Pasteur Institut
Priority to AU62937/98A priority Critical patent/AU6293798A/en
Publication of WO1998032849A2 publication Critical patent/WO1998032849A2/en
Publication of WO1998032849A3 publication Critical patent/WO1998032849A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention concerns a polynucleotide which is selected from the group consisting of: (a) a polynucleotide comprising at least 8 consecutive nucleotides of SEQ ID No. 1; (b) a polynucleotide differing from the polynucleotide defined in (a) by mutation, insertion, deletion of substitution of one or more bases; (c) a polynucleotide, the sequence of which is complementary to the sequence of anyone of polynucleotides defined in (a) and (b); (d) a polynucleotide which hybridizes specifically with anyone of the polynucleotides defined in (a), (b) or (c).
PCT/EP1998/000433 1997-01-29 1998-01-28 Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications WO1998032849A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62937/98A AU6293798A (en) 1997-01-29 1998-01-28 Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3657997P 1997-01-29 1997-01-29
US60/036,579 1997-01-29

Publications (2)

Publication Number Publication Date
WO1998032849A2 WO1998032849A2 (en) 1998-07-30
WO1998032849A3 true WO1998032849A3 (en) 1998-10-08

Family

ID=21889394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000433 WO1998032849A2 (en) 1997-01-29 1998-01-28 Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications

Country Status (2)

Country Link
AU (1) AU6293798A (en)
WO (1) WO1998032849A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340818A1 (en) 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
WO2012112955A2 (en) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
WO2014169294A1 (en) * 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations in dstyk cause dominant urinary tract malformations
CN112746104A (en) * 2021-01-22 2021-05-04 丁建强 Molecular marker for early diagnosis of liver injury diseases in serum
CN112646878A (en) * 2021-01-22 2021-04-13 丁建强 Molecular marker for early diagnosis of liver injury diseases in serum

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946773A (en) * 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
WO1996023903A1 (en) * 1995-01-30 1996-08-08 Ulf Landegren Method for detecting nucleic acid sequence variations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946773A (en) * 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
WO1996023903A1 (en) * 1995-01-30 1996-08-08 Ulf Landegren Method for detecting nucleic acid sequence variations

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABDELHAK S. ET AL.: "A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family", NATURE GENETICS, vol. 15, no. 2, February 1997 (1997-02-01), pages 157 - 164, XP002071634 *
AMERSHAM CATALOG 1996 "Scintillation proximity assay" p. 252 *
BERGER S.L. & KIMMEL A.R., EDS.: "Methods in Enzymolog vol 152: Guide to molecular cloning techniques", 1987, ACADEMIC PRESS, SAN DIEGO, XP002071636 *
BONINI N.M. ET AL.: "The eyes absent gene: genetic control of cell survival and differentiation in the developing drosophila eye.", CELL, vol. 72, 12 February 1993 (1993-02-12), pages 379 - 395, XP002071631 *
DATABASE GENBANK 2 June 1995 (1995-06-02), HILLIER L. ET AL.: "EST; H. sapiens clone 156327 sinilar to eya", XP002071638 *
DATABASE GENBANK 23 June 1995 (1995-06-23), HILLIER L. ET AL.: "EST; H. Sapiens clone 45134 similar to eya", XP002071637 *
KALATZIS V. ET AL.: "Characterization of a translocation-associated deletion defines the candidate region for the gene responsible for branchio-oto-renal syndrome", GENOMICS, vol. 34, no. 3, 15 June 1996 (1996-06-15), pages 422 - 425, XP002071633 *
MASATO ORITA ET AL: "DETECTION OF POLYMORPHISMS OF HUMAN DNA BY GEL ELECTROPHORESIS AS SINGLE-STRAND CONFORMATION POLYMORPHISMS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, no. 8, 1 April 1989 (1989-04-01), pages 2766 - 2770, XP000310584 *
XU P.X. ET AL.: "Mouse eya homologues of the Drosophila eyes absent gene require Pax6 for expression in lens and nasal placode", DEVELOPMENT, vol. 124, no. 1, January 1997 (1997-01-01), XP002071632 *

Also Published As

Publication number Publication date
WO1998032849A2 (en) 1998-07-30
AU6293798A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
AU4634396A (en) Dna sequences encoding carbohydrate polymer synthesizing enzymes and method for producing transgenic plants
EP1538155A3 (en) Amylase variants
BG106538A (en) Immunostimulatory nucleic acids
BG101355A (en) Viral material and nucleotide fragments related to multiplesclerosis, for the diagnostics, prophylaxy and treatment of thisdisease
CA2118071A1 (en) Dna encoding limonene synthase from mentha spicata
WO2002028891A3 (en) Listeria inocua, genome and applications
GR3021781T3 (en) Specific detection of mycobacterium tuberculosis
AU3230797A (en) Dna encoding dp. 75 and a process for its use
GB9310657D0 (en) Retrovirus
WO1998032849A3 (en) Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications
WO1999028439A3 (en) Erythrovirus and its applications
CA2114631A1 (en) N-acetylglucosaminyltransferase v coding sequences
AU8447098A (en) Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
AU2001279769A1 (en) Citb gene from corynebacteria and use thereof in synthesis of l-amino acids
AU2002214949A1 (en) Nucleotide sequences which code for the ppsa gene
AU2001279663A1 (en) Nucleotide sequences which code for the lysr2 gene
HUP0001969A2 (en) The neurotrophic factor nnt-1
WO1999002666A3 (en) Retroviral nucleic material and nucleotide fragments, in particular associated with multiple sclerosis and/or rheumatoid arthritis, for diagnostic, prophylactic and therapeutic uses
WO2002022666A3 (en) Nucleotide sequences which code for the gora gene
EP1291418A4 (en) Novel glycosyltransferase genes
AU2002219032A1 (en) Nucleotide sequences which code for the dep34 gene
AU2002214980A1 (en) Nucleotide sequences which code for the msik gene
EP0984061A4 (en) Sialidases localized on plasma membranes and dna encoding the same
WO2002020771A3 (en) Nucleotide sequences coding for the hisc2 gene
GB9609261D0 (en) Gene expression in monocytes and microphages

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09341709

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998531611

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase